The European Commission has granted its approval to Pfizer’s Velsipity for the treatment of ulcerative colitis in patients aged 16 and above, marking an advancement in addressing this condition. This decision, in line with the endorsement received from the European Medicines Agency in December, signifies a pivotal moment for the approximately 2.6 million individuals across Europe grappling with ulcerative colitis.
The approval encompasses all 27 European Union member countries and is based on data from two late-stage trials demonstrating the drug’s efficacy and safety profile in eligible patients. Pfizer has indicated that Velsipity will be made available in each member country once national processes, including reimbursement applications, are finalized.
Velsipity emerges as the inaugural and solitary oral therapy in its category tailored for advanced ulcerative colitis, offering hope for patients who have encountered limited relief with existing therapeutic options.
The road to approval was paved with compelling evidence from the ELEVATE UC Phase 3 registrational program, which underscored Velsipity’s effectiveness and safety profile among patients who had not adequately responded to or tolerated conventional biologic or Janus kinase inhibitor therapies. Noteworthy for its once-daily oral dosing regimen, Velsipity distinguishes itself with its convenience and favorable benefit-risk ratio, potentially reshaping the treatment landscape for eligible patients as young as 16 within the European Union, Iceland, Liechtenstein, and Norway.
As healthcare systems across the EU member states, Iceland, Liechtenstein, and Norway prepare to integrate this therapy into their treatment protocols, attention inevitably shifts to matters of patient access and affordability. Additionally, ongoing monitoring of the drug’s real-world performance and patient outcomes will provide insights for future research and development endeavors in the realm of inflammatory bowel diseases.
Projections anticipate Velsipity to achieve sales of $2.2 billion by 2030, positioning it to exert considerable influence in the global ulcerative colitis market, classified within a class of drugs aimed at modulating the body’s immune response, it will directly compete with Bristol Myers Squibb’s Zeposia.
The drug’s approval in the United States in October foreshadowed its current success in the European Union, with Pfizer actively pursuing regulatory authorizations in other regions such as Australia, India, and the UK. This expansive approach underscores Pfizer’s dedication to addressing the unmet needs of ulcerative colitis patients worldwide by offering a viable and accessible treatment option that was previously lacking.
Overall, Pfizer’s Velsipity, newly approved by the European Commission for ulcerative colitis treatment, follows endorsement from the European Medicines Agency. Cleared for patients 16+, it’s supported by data from trials, aiming to address the condition’s unmet needs across 27 EU countries. Sales forecasts project significant revenue growth, with global regulatory efforts ongoing.
